Survival Outcome of Inoperable Non-Small Cell Lung Cancer Patients Receiving Conventional Dose Epirubicin and Paclitaxel as First-Line Treatment

Oncology ◽  
2005 ◽  
Vol 68 (4-6) ◽  
pp. 350-355 ◽  
Author(s):  
Chih-Hsin Yang ◽  
Min-Chun Chen ◽  
Ann-Lii Cheng ◽  
Chih-Hung Hsu ◽  
Kun-Huei Yeh ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Survival Outcome ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
Lung Cancer Patients ◽  
Conventional Dose ◽  
First Line Treatment

scholarly journals Bevacizumab, pemetrexed and carboplatin in first-line treatment of non-small cell lung cancer patients: Focus on patients with brain metastases

2016 ◽  
Vol 12 (6) ◽  
pp. 4635-4642 ◽  
Author(s):  
Dimitra Stefanou ◽  
Sofia Stamatopoulou ◽  
Antigoni Sakellaropoulou ◽  
Gavriil Akakios ◽  
Marina Gkiaouraki ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
Lung Cancer Patients ◽  
First Line Treatment

scholarly journals KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor

ESMO Open ◽  
2021 ◽  
Vol 6 (5) ◽  
pp. 100279
Author(s):  
R. Serna-Blasco ◽  
E. Sánchez-Herrero ◽  
S. Sanz-Moreno ◽  
A. Rodriguez-Festa ◽  
E. García-Veros ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Kinase Inhibitor ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
Lung Cancer Patients ◽  
Egfr Mutated ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document